Axios

Since January, pharmaceutical giant Pfizer has raised the list prices of 91 drugs by an average of 20%, the Financial Times reports. Pfizer made one round of price increases in January, and another just went into effect. The list price does not factor in rebates or discounts, but Pfizer's increases are still far beyond the rate of economic inflation.

Why it matters: Politicians and consumers have ripped into the drug industry and have strongly supported proposals to lower drug costs. Some companies have made pledges to limit price hikes. But Pfizer's decision indicates public pressure has not forced companies to change their pricing practices, and some firms have no qualms about maintaining the status quo.

Health care organizations have slowed their pace of hiring, but the industry is still anchoring American job growth. Health care added 24,300 jobs in May, according to the Bureau of Labor Statistics. Health care employment has risen by 108,000 jobs so far in 2017.

Food for thought: Many jobs in hospitals and outpatient centers provide decent incomes, but the hiring boom has turned into a major problem for a health care system that cannot control spending. The rising costs of employee salaries and benefits, coupled with stagnant or declining federal payments, could lead to layoffs at hospitals.

Nebraskans face the dire prospect of having no individual health insurance options in the Affordable Care Act market, the Omaha World Herald reports. Blue Cross and Blue Shield of Nebraska already had pulled out of most of its ACA plans, and the last insurer, Medica, is wavering and hasn't made a final decision yet.

Why it matters: Nebraska's ACA marketplace is starting to resemble its neighbor Iowa's, which poses problems for tens of thousands of people buying health coverage on their own.